Twist Bioscience Corporation (NASDAQ:TWST) Q1 2026 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) Q1 2026 Earnings Call Transcript February 2, 2026Twist Bioscience Corporation misses on earnings expectations.
Twist Bioscience Corp (TWST)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 7,559,495 | $239,787,194 | +13% | 1.59% |
| 2. | Soleus Capital Guy Levy | 1,861,802 | $59,056,359 | -1% | 2.18% |
| 3. | Millennium Management Israel Englander | 1,497,746 | $47,508,503 | -17% | 0.02% |
| 4. | Tao Capital Nicholas J. Pritzker | 828,815 | $26,290,012 | 22.63% | |
| 5. | Balyasny Asset Management Dmitry Balyasny | 579,370 | $18,377,616 | +136% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.20 | 10,000 | $132,000.00 | 29,297 | 2023-05-10 | Filing | |
| $29.25 | 8,550 | $250,096.05 | 13,939 | 2022-05-11 | Filing | |
| $14.00 | 60,000 | $840,000.00 | 954,146 | 2018-11-02 | Filing | |
| $14.00 | 15,000 | $210,000.00 | 2,407,422 | 2018-11-02 | Filing | |
| $14.00 | 60,000 | $840,000.00 | 954,146 | 2018-11-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.79 | 354 | $15,500.39 | 137,903 | 2026-03-20 | Filing | |
| $43.79 | 297 | $13,004.56 | 124,104 | 2026-03-20 | Filing | |
| $43.79 | 1,742 | $76,275.91 | 858,887 | 2026-03-20 | Filing | |
| $47.00 | 10,000 | $470,000.00 | 21,084 | 2026-03-17 | Filing | |
| $46.43 | 246 | $11,420.80 | 54,799 | 2026-03-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,954,429 | $188,874,488 | 0.53% | |
| 2. | 5,894,972 | $186,988,511 | 0% | |
| 3. | 5,830,205 | $184,934,095 | 0.28% | |
| 4. | 5,776,198 | $183,221,001 | 0% | |
| 5. | 5,377,991 | $170,589,875 | 1.4% |
News See All
Twist Bioscience Corporation (TWST): A Bull Case Theory
We came across a bullish thesis on Twist Bioscience Corporation on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on TWST.
Barclays Keeps Its Overweight Rating On Twist Bioscience Corporation (TWST)
TheFly reported on December 15, 2025, that Barclays kept its Overweight rating and boosted its price objective for Twist Bioscience Corporation (NASDAQ:TWST) from $37 to $39.
12 Best Genomics Stocks to Invest In
Companies that study DNA to improve people's lives are known as genomics stocks.
7 Most Promising Gene Editing Stocks According to Analysts
Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells.
Stephens Initiates Twist Bioscience (TWST) With Overweight Rating, Sets $41 PT
Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Is Twist Bioscience Corporation (TWST) a Compelling Risk-Regarded Opportunity?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Twist Bioscience Corporation (NASDAQ:TWST) Q4 2025 Earnings Call Transcript
Operator: Welcome to Twist Biosciences 2025 Fourth Quarter Financial Results Conference Call. [Operator Instructions] Please note, this conference is being recorded.
Multiple Headwinds Hit Twist BioScience Corp. (TWST) in Q3
Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center